Efficacy and Safety of Corticosteroids in COVID-19

Capital Medical University

Status: Completed

Conditions: COVID-19; Novel Coronavirus Pneumonia

Treatments: Drug: Methylprednisolone

Study type: Interventional

Funder types: Other

Identifiers

NCT04273321

Methylprednisolone in COVID-19

Details and patient eligibility

About

There is still controversy about the effective of glucocorticoids for the treatment of novel coronavirus pneumonia. This is a prospective randomized controlled trails. The aim is to explore the effectiveness and safety of glucocorticoids in the treatment of novel coronavirus pneumonia.

Enrollment: 86 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age more than 18 years old
• accord with the clinical diagnosis and/ or etiological diagnosis diagnostic criteria of Novel coronavirus pneumonia (COVID-19).
• admitted in the general wards
• be able to sign informed consent

Exclusion criteria

• severe immunosuppression (HIV infection, long-term use of immunosuppressive agents
• pregnant or lactation period women
• glucocorticoids are needed for other diseases
• unwilling or unable to participate or complete the study
• participate in other study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

86 participants in 2 patient groups

MP group

Experimental group

Treatment:

Drug: Methylprednisolone

Con group

No Intervention group